KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Depreciation & Amortization (CF) (2016 - 2025)

Acadia Pharmaceuticals (ACAD) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $202000.0 in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) fell 1.94% year-over-year to $202000.0; the TTM value through Dec 2025 reached $871000.0, down 3.22%, while the annual FY2025 figure was $871000.0, 3.22% down from the prior year.
  • Depreciation & Amortization (CF) reached $202000.0 in Q4 2025 per ACAD's latest filing, down from $227000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $616000.0 in Q3 2021 and bottomed at $202000.0 in Q4 2025.
  • Average Depreciation & Amortization (CF) over 5 years is $374600.0, with a median of $380500.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 82.25% in 2021, then plummeted 44.38% in 2023.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $535000.0 in 2021, then dropped by 8.6% to $489000.0 in 2022, then tumbled by 44.38% to $272000.0 in 2023, then fell by 24.26% to $206000.0 in 2024, then dropped by 1.94% to $202000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $202000.0 in Q4 2025, $227000.0 in Q3 2025, and $213000.0 in Q2 2025.